We are thrilled to announce that TetraKit Technologies’ lead compound DualFAPi (a FAP-targeted dimer designed to prolong tumor residence) has been selected as one of three candidates for clinical evaluation under the prestigious Accelerate.EU initiative. This innovative €16 million project, funded by the Institute for Health Innovation (IHI), is a major step forward for our team and drives European leadership in alpha cancer therapies.

The Accelerate.EU initiative aims to create a complete value chain for astatine-211 (211At), one of the most promising alpha particle emitters for cancer therapy, and we are proud to contribute to this effort. This project will push the boundaries of cancer treatment by pioneering theranostic approaches that combine tumor-targeted radiation with advanced imaging technologies.

We at TetraKit are delighted to be part of this initiative, dedicated to addressing critical clinical challenges in aggressive cancers such as triple negative breast cancer (TNBC), pancreatic cancer and glioblastoma.

Our participation in Accelerate.EU opens up opportunities to:

1. Expand our expertise in 211At-labeling and theranostic radiopharmaceuticals

2. Lead the development of innovative radiotherapeutic agents, such as our 211At-DualFAPi and 123I-DualFAPi compounds, which will be evaluated in a Phase 1 clinical trial against TNBC under the project.

3. Reinforcing our position at the forefront of radiopharmaceutical innovation, in close collaboration with esteemed partners across Europe.

This achievement would not have been possible without the collaboration and dedication of our partners, including IBA, the Københavns Universitet – University of Copenhagen (KU), Rigshospitalet and the entire Accelerate.EU consortium. Special thanks to IBA and the Institut Jules Bordet for their exceptional coordination and to IHI for their support and recognition of our shared vision for the future of cancer treatment.

We look forward to continuing this exciting journey together as we strive to revolutionize cancer care and offer new hope to patients with limited treatment options.

Stay tuned for more updates as we move forward on this transformative journey! 🚀

Accelerate.EU – communication and press release PDF: https://tetrakit.com/wp-content/uploads/2024/10/1728310235869.pdf